Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa.
| Revenue (Most Recent Fiscal Year) | $0.44M |
| Net Income (Most Recent Fiscal Year) | $-35.13M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.92 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -10451.70% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -48.48% |
| Return on Assets (Trailing 12 Months) | -35.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.44 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.44 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $12.80 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.92 |
| Earnings per Share (Most Recent Fiscal Year) | $-20.91 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 13.15M |
| Free Float | 13.12M |
| Market Capitalization | $117.45M |
| Average Volume (Last 20 Days) | 0.30M |
| Beta (Past 60 Months) | 0.80 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.25% |
| Percentage Held By Institutions (Latest 13F Reports) | 87.06% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |